Incident Cardiovascular, Thromboembolic, and Safety Outcomes of JAK Inhibitors Versus TNF Inhibitors in Seropositive Rheumatoid Arthritis: A Propensity Score-Matched Real-World Analysis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1411; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Adults 18-90 with seropositive RA (ICD-10 M05; cohorts defined by ICD-10 coding rather than ACR classification criteria) were split into mutually exclusive JAKi initiators (tofacitinib, baricitinib, upadacitinib) without TNFi exposure and TNFi initiators (adalimumab, etanercept, infliximab, golimumab, certolizumab) without JAKi exposure. In this large PSM real-world cohort of seropositive RA with all outcomes restricted to incident events, JAKi use was associated with higher 3-year risks of AMI, heart failure, and VTE – extending the ORAL Surveillance signal to a broad, unselected population using clean incident outcomes. Incident T2DM and lymphoma did not differ; apparent excesses seen without prevalent-disease exclusion did not persist after incident restriction, underscoring the importance of baseline exclusion. Lower tuberculosis with JAKi is consistent with the TB-reactivation risk of TNFi."
Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Ischemic stroke • Lymphoma • Obesity • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Tuberculosis • Type 2 Diabetes Mellitus
|
|
gurjot singh1; Kevin Hannah2; Godbless Ajenaghughrure1; Sila Mateo Faxas1; Dharana Gelal3
|